Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
C CARDIOVASCULAR SYSTEM
C01 CARDIAC THERAPY
C01E OTHER CARDIAC PREPARATIONS
C01EB Other cardiac preparations
C01EB17 Ivabradine
D08095 Ivabradine hydrochloride (JAN/USAN) <JP/US>
USP drug classification [BR:br08302]
Cardiovascular Agents
Cardiovascular Agents, Other
Ivabradine
D08095 Ivabradine hydrochloride (JAN/USAN)
Therapeutic category of drugs in Japan [BR:br08301]
2 Agents affecting individual organs
21 Cardiovascular agents
219 Miscellaneous
2190 Miscellaneous
D08095 Ivabradine hydrochloride (JAN/USAN)
Drug groups [BR:br08330]
Metabolizing enzyme substrate
DG01633 CYP3A/CYP3A4 substrate
DG02913 CYP3A4 substrate
DG00246 Ivabradine
D08095 Ivabradine hydrochloride
Target-based classification of drugs [BR:br08310]
Ion channels
Other ion channels
Hyperpolarization-activated ion channel
HCN
D08095 Ivabradine hydrochloride (JAN/USAN) <JP/US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D08095
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D08095
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D08095
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D08095
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D08095
Drug groups [BR:br08330]
Metabolizing enzyme substrate
DG01633 CYP3A/CYP3A4 substrate
DG02913 CYP3A4 substrate
DG00246 Ivabradine